This clinical trial aims to find a better drug concentration of Remifentanil in Uterine Fibroid Ablation. The main question it seeks to answer is:
\[primary hypothesis 1\] Remifentanil concentration of 2.0 ng/mL provides better pain control in Uterine Fibroid Ablation.
There is a comparison group in this study: Researchers will compare Remifentanil concentration of 1.0 ng/mL to see if provides similar pain control with fewer side effects.
Participants will be separated into two groups, one group with a Remifentanil concentration of 2.0 ng/mL and the other 1.0 ng/mL. During uterine fibroid ablation, the patient\'s pain index will be recorded (using a Visual Analogue Scale (VAS) of 0\~10 points). We will also record vital signs during the procedure.
Aged between 20 and 65 years old
American Society of Anesthesiology classification I~III
Female patients diagnosed with uterine fibroids by obstetricians and gynecologists
Patients with heart disease (such as arrhythmia or severe ventricular dysfunction)
Patients with chronic kidney disease in stage III or above or dialysis patients
Long-term alcohol addiction or drug abuse
Patients with abnormal liver index or chronic hepatitis